Perioperative immunotherapy for hepatocellular carcinoma: adjuvant, neoadjuvant, and biomarker-guided strategies
Hepatocellular carcinoma (HCC) remains difficult to cure after resection or ablation, with high recurrence rates. Perioperative immunotherapy has rapidly evolved, but recent late-phase readouts highlight that benefit is not universal. In IMbrave050, adjuvant atezolizumab plus bevacizumab initially i...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2026-04-01
|
| coleção: | Frontiers in Medicine |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1811918/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|